Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30475447 | 0.83 | CRBN (0.41) | CRBNDDB1CYP3A4CYP2D6TSHR | |
| SCHEMBL30112373 | 0.82 | CRBN (0.39) | CRBNDDB1POLB | |
| SCHEMBL24880669 | 0.82 | CRBN (0.39) | CRBNDDB1POLB | |
| SCHEMBL25825240 | 0.81 | CRBN (0.41) | CRBNDDB1POLB | |
| SCHEMBL26641599 | 0.80 | CRBN (0.52) | CRBNDDB1POLB | |
| SCHEMBL31727001 | 0.80 | CRBN (0.52) | CRBNDDB1POLB | |
| SCHEMBL24671499 | 0.79 | CRBN (0.45) | CRBNDDB1POLB | |
| SCHEMBL24671266 | 0.78 | CRBN (0.44) | CRBNDDB1POLB | |
| SCHEMBL25188466 | 0.78 | KDM4E (0.51) | CRBNDDB1HSD17B10POLB | |
| SCHEMBL25192137 | 0.78 | KDM4E (0.51) | CRBNDDB1HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885CYP3A4 4760/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | CRBN 2496/4885DDB1 77/4885CYP3A4 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.